AAAAAA

   
Results: 1-25 | 26-29
Results: 1-25/29
Tumor necrosis factor-alpha-promoted expression of Bcl-2 and inhibition ofmitochondrial cytochrome c release mediate resistance of mature dendritic cells to melanoma-induced apoptosis
Authors: Esche, C Shurin, GV Kirkwood, JM Wang, GQ Rabinowich, H Pirtskhalaishvili, G Shurin, MR
Citation: C. Esche et al., Tumor necrosis factor-alpha-promoted expression of Bcl-2 and inhibition ofmitochondrial cytochrome c release mediate resistance of mature dendritic cells to melanoma-induced apoptosis, CLIN CANC R, 7(3), 2001, pp. 974S-979S
High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup trial E1694/S9512/C509801
Authors: Kirkwood, JM Ibrahim, JG Sosman, JA Sondak, VK Agarwala, SS Ernstoff, MS Rao, U
Citation: Jm. Kirkwood et al., High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: Results of Intergroup trial E1694/S9512/C509801, J CL ONCOL, 19(9), 2001, pp. 2370-2380
High-dose interferon alfa-2b does mot diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the multicenter Eastern Cooperative Oncology Group phase II trial E2696
Authors: Kirkwood, JM Ibrahim, J Lowson, DH Aikins, MB Agarwala, SS Collins, K Mascari, R Morrissey, DM Chapman, PB
Citation: Jm. Kirkwood et al., High-dose interferon alfa-2b does mot diminish antibody response to GM2 vaccination in patients with resected melanoma: Results of the multicenter Eastern Cooperative Oncology Group phase II trial E2696, J CL ONCOL, 19(5), 2001, pp. 1430-1436
Adjuvant therapy of melanoma: At what cost? In reply
Authors: Kirkwood, JM
Citation: Jm. Kirkwood, Adjuvant therapy of melanoma: At what cost? In reply, J CL ONCOL, 19(4), 2001, pp. 1226-1228
Patient preferences for adjuvant interferon alfa-2b treatment
Authors: Kilbridge, KL Weeks, JC Sober, AJ Haluska, FG Slingluff, CL Atkins, MB Sock, DE Kirkwood, JM Nease, RF
Citation: Kl. Kilbridge et al., Patient preferences for adjuvant interferon alfa-2b treatment, J CL ONCOL, 19(3), 2001, pp. 812-823
High-dose interferon versus GM2 vaccine in high-risk malignant melanoma - Reply
Authors: Kirkwood, JM Ibrahim, J Manola, J
Citation: Jm. Kirkwood et al., High-dose interferon versus GM2 vaccine in high-risk malignant melanoma - Reply, J CL ONCOL, 19(23), 2001, pp. 4350-4350
Rhabdomyolysis, when observed with high-dose interferon-alfa (HDI) therapy, does not always exclude resumption of HDI
Authors: van Londen, GJ Mascarenhas, B Kirkwood, JM
Citation: Gj. Van Londen et al., Rhabdomyolysis, when observed with high-dose interferon-alfa (HDI) therapy, does not always exclude resumption of HDI, J CL ONCOL, 19(17), 2001, pp. 3794-3794
Prognostic factors analysis of 17,600 melanoma patients: Validation of theAmerican Joint Committee on Cancer melanoma staging system
Authors: Balch, CM Soong, SJ Gershenwald, JE Thompson, JF Reintgen, DS Cascinelli, N Urist, M McMasters, KM Ross, MI Kirkwood, JM Atkins, MB Thompson, JA Coit, DG Byrd, D Desmond, R Zhang, YT Liu, PY Lyman, GH Morabito, A
Citation: Cm. Balch et al., Prognostic factors analysis of 17,600 melanoma patients: Validation of theAmerican Joint Committee on Cancer melanoma staging system, J CL ONCOL, 19(16), 2001, pp. 3622-3634
Final version of the American Joint Committee on Cancer staging system forcutaneous melanoma
Authors: Balch, CM Buzaid, AC Soong, SJ Atkins, MB Cascinelli, N Coit, DG Fleming, ID Gershenwald, JE Houghton, A Kirkwood, JM McMasters, KM Mihm, MF Morton, DL Reintgen, DS Ross, MI Sober, A Thompson, JA Thompson, JF
Citation: Cm. Balch et al., Final version of the American Joint Committee on Cancer staging system forcutaneous melanoma, J CL ONCOL, 19(16), 2001, pp. 3635-3648
Burden of illness associated with metastatic melanoma - An audit of 100 consecutive referral center cases
Authors: Hillner, BE Kirkwood, JM Agarwala, SS
Citation: Be. Hillner et al., Burden of illness associated with metastatic melanoma - An audit of 100 consecutive referral center cases, CANCER, 91(9), 2001, pp. 1814-1821
Phase I, randomized, double-blind trial of 7-allyl-8-oxoguanosine (loxoribine) in advanced cancer
Authors: Agarwala, SS Kirkwood, JM Bryant, J
Citation: Ss. Agarwala et al., Phase I, randomized, double-blind trial of 7-allyl-8-oxoguanosine (loxoribine) in advanced cancer, CYTOK CELL, 6(4), 2000, pp. 171-176
Phase II study of etoposide (VP-16) in patients with thyroid cancer with no prior chemotherapy: an Eastern Cooperative Oncology Group Study (E1385)
Authors: Leaf, AN Wolf, BC Kirkwood, JM Haselow, RE
Citation: An. Leaf et al., Phase II study of etoposide (VP-16) in patients with thyroid cancer with no prior chemotherapy: an Eastern Cooperative Oncology Group Study (E1385), MED ONCOL, 17(1), 2000, pp. 47-51
Interleukin-2: Developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity
Authors: Lotze, MT Shurin, M Esche, C Tahara, H Storkus, W Kirkwood, JM Whiteside, TL Elder, EM Okada, H Robbins, P
Citation: Mt. Lotze et al., Interleukin-2: Developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity, CA J SCI AM, 6, 2000, pp. S61-S66
Granulocyte-macrophage colony-stimulating factor: Another cytokine with adjuvant therapeutic benefit in melanoma?
Authors: Lawson, D Kirkwood, JM
Citation: D. Lawson et Jm. Kirkwood, Granulocyte-macrophage colony-stimulating factor: Another cytokine with adjuvant therapeutic benefit in melanoma?, J CL ONCOL, 18(8), 2000, pp. 1603-1605
High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of Intergroup Trial E1690/S9111/C9190
Authors: Kirkwood, JM Ibrahim, JG Sondak, VK Richards, J Flaherty, LE Ernstoff, MS Smith, TJ Rao, U Steele, M Blum, RH
Citation: Jm. Kirkwood et al., High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of Intergroup Trial E1690/S9111/C9190, J CL ONCOL, 18(12), 2000, pp. 2444-2458
Biologic therapy
Authors: Edington, H Agarwala, S Kirkwood, JM
Citation: H. Edington et al., Biologic therapy, CLIN PLAST, 27(4), 2000, pp. 643
Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitoperecognized by melanoma-reactive CD4(+) T cells
Authors: Zarour, HM Kirkwood, JM Kierstead, LS Herr, W Brusic, V Slingluff, CL Sidney, J Sette, A Storkus, WJ
Citation: Hm. Zarour et al., Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitoperecognized by melanoma-reactive CD4(+) T cells, P NAS US, 97(1), 2000, pp. 400-405
NY-ESO-1 encodes DRB10401-restricted epitopes recognized by melanoma-reactive CD4+T cells
Authors: Zarour, HM Storkus, WJ Brusic, V Williams, E Kirkwood, JM
Citation: Hm. Zarour et al., NY-ESO-1 encodes DRB10401-restricted epitopes recognized by melanoma-reactive CD4+T cells, CANCER RES, 60(17), 2000, pp. 4946-4952
A new American Joint Committee on Cancer staging system for cutaneous melanoma
Authors: Balch, CM Buzaid, AC Atkins, MB Cascinelli, N Coit, DG Fleming, ID Houghton, A Kirkwood, JM Mihm, MF Morton, DL Reintgen, D Ross, MI Sober, A Soong, SJ Thompson, JA Thompson, JF Gershenwald, JE McMasters, KM
Citation: Cm. Balch et al., A new American Joint Committee on Cancer staging system for cutaneous melanoma, CANCER, 88(6), 2000, pp. 1484-1491
Analysis of therapeutic and immunologic effects of R-24 anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma
Authors: Kirkwood, JM Mascari, RA Edington, RD Rabkin, MS Day, RS Whiteside, TL Vlock, DR Shipe-Spotloe, JM
Citation: Jm. Kirkwood et al., Analysis of therapeutic and immunologic effects of R-24 anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma, CANCER, 88(12), 2000, pp. 2693-2702
Adjuvant interferon in the treatment of melanoma
Authors: Kirkwood, JM
Citation: Jm. Kirkwood, Adjuvant interferon in the treatment of melanoma, BR J CANC, 82(10), 2000, pp. 1755-1755
Adjuvant therapy of melanoma
Authors: Agarawala, SS Kirkwood, JM
Citation: Ss. Agarawala et Jm. Kirkwood, Adjuvant therapy of melanoma, STRATEGIES IN ADJUVANT THERAPY, 2000, pp. 93-103
Melanoma - Immunotherapeutic approaches
Authors: Agarwala, SS Kirkwood, JM
Citation: Ss. Agarwala et Jm. Kirkwood, Melanoma - Immunotherapeutic approaches, BIODRUGS, 12(3), 1999, pp. 193-208
Macroscopic spectral imaging and gene expression analysis of the early stages of melanoma
Authors: Yang, P Farkas, DL Kirkwood, JM Abernethy, JL Edington, HD Becker, D
Citation: P. Yang et al., Macroscopic spectral imaging and gene expression analysis of the early stages of melanoma, MOL MED, 5(12), 1999, pp. 785-794
Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions
Authors: Kirkwood, JM Farkas, DL Chakraborty, A Dyer, KF Tweardy, DJ Abernethy, JL Edington, HD Donnelly, SS Becker, D
Citation: Jm. Kirkwood et al., Systemic interferon-alpha (IFN-alpha) treatment leads to Stat3 inactivation in melanoma precursor lesions, MOL MED, 5(1), 1999, pp. 11-20
Risultati: 1-25 | 26-29